Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI)

NCT: NCT05186948 · TERMINATED

NCT IDNCT05186948
StatusTERMINATED
Start Date2022-03-30
Completion2025-01-20

Brief Summary

This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.

Frequently Asked Questions

What is Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI)?

Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI) is a clinical trial registered under NCT05186948. Current status: TERMINATED.

What is the status of NCT05186948?

The current status of NCT05186948 (Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI)) is: TERMINATED.

When did Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI) start?

Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairment (CRCI) started on 2022-03-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑